+

WO1999006032A3 - Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion - Google Patents

Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion Download PDF

Info

Publication number
WO1999006032A3
WO1999006032A3 PCT/ES1998/000204 ES9800204W WO9906032A3 WO 1999006032 A3 WO1999006032 A3 WO 1999006032A3 ES 9800204 W ES9800204 W ES 9800204W WO 9906032 A3 WO9906032 A3 WO 9906032A3
Authority
WO
WIPO (PCT)
Prior art keywords
solution
nebulisation
excipient
covering
production
Prior art date
Application number
PCT/ES1998/000204
Other languages
English (en)
French (fr)
Other versions
WO1999006032A2 (es
Inventor
Darder Carlos Picornell
Original Assignee
Intexim S A
Darder Carlos Picornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8300432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999006032(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DE69833490T priority Critical patent/DE69833490T2/de
Priority to IL13415898A priority patent/IL134158A/en
Priority to AU82173/98A priority patent/AU751609B2/en
Priority to HU0002524A priority patent/HU230635B1/hu
Priority to CA002307037A priority patent/CA2307037C/en
Priority to KR1020007001023A priority patent/KR100591488B1/ko
Priority to SK103-2000A priority patent/SK284892B6/sk
Application filed by Intexim S A, Darder Carlos Picornell filed Critical Intexim S A
Priority to NZ502590A priority patent/NZ502590A/en
Priority to JP2000504847A priority patent/JP3961217B2/ja
Priority to UA2000020750A priority patent/UA66800C2/uk
Priority to EP98932185A priority patent/EP1010423B1/en
Priority to PL338613A priority patent/PL192961B1/pl
Publication of WO1999006032A2 publication Critical patent/WO1999006032A2/es
Publication of WO1999006032A3 publication Critical patent/WO1999006032A3/es
Priority to US09/491,624 priority patent/US20020098242A1/en
Priority to NO20000435A priority patent/NO20000435L/no
Priority to HR20000053A priority patent/HRP20000053B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Comprende un núcleo inerte; una capa activa soluble o de desintegración rápida en agua obtenida a partir de una única solución-suspensión acuosa o hidroalcohólica que comprende: un principio activo de actividad antiulcerosa de fórmula (I, II ó III), y por lo menos un excipiente; y una capa de recubrimiento externa gastrorresistente obtenida a partir de una solución que comprende: un polímero de recubrimiento entérico; y por lo menos un excipiente. El procedimiento se lleva a cabo mediante 1) un recubrimiento de los núcleos inertes mediante la nebulización de la única suspensión-solución acuosa o hidroalcohólica; 2) un secado de la capa activa formada durante la nebulización de la etapa anterior; y 3) un recubrimiento de los núcleos cargados mediante la nebulización de una solución que comprende un polímero de recubrimiento entérico con por lo menos un excipiente para obtener una capa de recubrimiento externa gastrorresistente.
PCT/ES1998/000204 1997-07-31 1998-07-13 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion WO1999006032A2 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
PL338613A PL192961B1 (pl) 1997-07-31 1998-07-13 Sposób wytwarzania doustnej kompozycji farmaceutycznej i doustna kompozycja farmaceutyczna
NZ502590A NZ502590A (en) 1997-07-31 1998-07-13 Anti-ulcer oral pharmaceutical preparation produced in a fluidized bed coater
AU82173/98A AU751609B2 (en) 1997-07-31 1998-07-13 Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
HU0002524A HU230635B1 (hu) 1997-07-31 1998-07-13 Eljárás fekélyellenes hatóanyagot tartalmazó orális gyógyászati készítmények előállítására
CA002307037A CA2307037C (en) 1997-07-31 1998-07-13 Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
KR1020007001023A KR100591488B1 (ko) 1997-07-31 1998-07-13 항궤양 활성 화합물을 포함하는 경구용 약제학적 제제의 제조방법
SK103-2000A SK284892B6 (sk) 1997-07-31 1998-07-13 Orálny farmaceutický prostriedok obsahujúci zlúčeninu s protivredovou aktivitou a spôsob jeho prípravy
DE69833490T DE69833490T2 (de) 1997-07-31 1998-07-13 Orale pharmazeutische zusammensetzung enthaltend ein benzimidazolderivat mit antiulcus wirkung und verfahren zu seiner herstellung
JP2000504847A JP3961217B2 (ja) 1997-07-31 1998-07-13 抗潰瘍活性化合物を含んでなる経口医薬製剤およびその製造方法
UA2000020750A UA66800C2 (uk) 1997-07-31 1998-07-13 Фармацевтична форма препарату для перорального прийому, що містить сполуку з противиразковою активністю, і спосіб її одержання
IL13415898A IL134158A (en) 1997-07-31 1998-07-13 Oral pharmacy preparations containing active compounds against gastric ulcer and process for their manufacture
EP98932185A EP1010423B1 (en) 1997-07-31 1998-07-13 Oral pharmaceutical preparation comprising an antiulcer benzimidazole derivative, and process for its production
US09/491,624 US20020098242A1 (en) 1997-07-31 2000-01-26 Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
NO20000435A NO20000435L (no) 1997-07-31 2000-01-27 Oralt farmasoytisk preparat omfattende en forbindelse med anti-ulceraktivitet og fremgangsmate for dets fremstilling
HR20000053A HRP20000053B1 (en) 1997-07-31 2000-01-31 Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009701816A ES2137862B1 (es) 1997-07-31 1997-07-31 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
ESP9701816 1997-07-31

Publications (2)

Publication Number Publication Date
WO1999006032A2 WO1999006032A2 (es) 1999-02-11
WO1999006032A3 true WO1999006032A3 (es) 1999-08-12

Family

ID=8300432

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES1998/000204 WO1999006032A2 (es) 1997-07-31 1998-07-13 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion

Country Status (33)

Country Link
US (1) US20020098242A1 (es)
EP (1) EP1010423B1 (es)
JP (1) JP3961217B2 (es)
KR (1) KR100591488B1 (es)
AR (1) AR013242A1 (es)
AT (1) ATE317688T1 (es)
AU (1) AU751609B2 (es)
BG (1) BG64967B1 (es)
CA (1) CA2307037C (es)
CR (1) CR5826A (es)
CZ (1) CZ298700B6 (es)
DE (1) DE69833490T2 (es)
DK (1) DK1010423T3 (es)
ES (3) ES2137862B1 (es)
GT (1) GT199800113A (es)
HN (1) HN1998000113A (es)
HR (1) HRP20000053B1 (es)
HU (1) HU230635B1 (es)
IL (1) IL134158A (es)
MY (1) MY121353A (es)
NO (1) NO20000435L (es)
NZ (1) NZ502590A (es)
PA (1) PA8456401A1 (es)
PE (1) PE105199A1 (es)
PL (1) PL192961B1 (es)
PT (1) PT1010423E (es)
RU (1) RU2207114C2 (es)
SK (1) SK284892B6 (es)
TR (1) TR200000264T2 (es)
TW (1) TW533201B (es)
UA (1) UA66800C2 (es)
WO (1) WO1999006032A2 (es)
ZA (1) ZA986893B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
BR0115585A (pt) 2000-11-28 2005-12-13 Fmc Corp Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
KR100447085B1 (ko) * 2001-11-08 2004-09-04 바램제약주식회사 마그네슘이온, 칼슘이온 또는 철이온이 고농도로 결합된알긴산의 제조 방법
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
IL161983A0 (en) * 2001-11-21 2005-11-20 Eisai Co Ltd Preparation compositions containing acid-unstable physiologically active compounds, and process for producing the same
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
PT1524967E (pt) * 2002-08-02 2008-04-03 Ratiopharm Gmbh Preparação farmacêutica contendo um composto de benzimidazole misturado com celulose microcristalina e método para a sua preparação.
CA2503150A1 (en) * 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
JP2006521366A (ja) * 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
RU2381813C2 (ru) 2004-03-22 2010-02-20 Зольвай Фармасьютиклз Гмбх Пероральные фармацевтические композиции на основе продуктов, содержащих липазы, прежде всего панкреатин, и пав
AU2005225283B2 (en) * 2004-03-26 2008-09-18 Eisai R&D Management Co., Ltd. Controlled-release pharmaceutical composition and method for producing the same
CN1938006B (zh) 2004-03-31 2010-11-10 Bpsi控股公司 用于口服摄取基质的肠溶包衣
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
EP1811979B1 (en) * 2004-09-27 2008-11-05 Sigmoid Pharma Limited Microcapsules comprising a methylxanthine and a corticosteroid
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
AU2005299490C1 (en) 2004-10-21 2012-01-19 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
BRPI0500586A (pt) * 2005-02-21 2006-10-10 Fundacao Oswaldo Cruz composição farmacêutica, processo para preparar dita composição, uso da respectiva composição no tratamento da imunodeficiência causada por infecção pelo hiv e respectivo método de tratamento
WO2006111980A2 (en) * 2005-04-20 2006-10-26 Ideal Cures Pvt. Ltd. Pva based film coating and film coating compositions
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
ES2597381T3 (es) 2005-07-29 2017-01-18 Abbott Laboratories Gmbh Procesos para la fabricación de polvo de pancreatina con bajo contenido en virus
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
CN103933555B (zh) 2007-02-20 2018-06-01 阿普塔利斯制药有限公司 稳定的消化酶组合物
CN103120653B (zh) 2007-04-04 2015-09-30 希格默伊德药业有限公司 一种口服药物组合物
CA2685118C (en) * 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2008132712A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions
WO2009069280A1 (ja) * 2007-11-27 2009-06-04 Ohara Pharmaceutical Co., Ltd. 造粒物の製造法
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
EP2293782B1 (en) * 2008-05-06 2015-08-12 Dexcel Pharma Technologies Ltd. Stable benzimidazole formulation
US8840934B2 (en) * 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
SI2432455T1 (sl) 2009-05-18 2015-04-30 Sigmoid Pharma Limited Sestava, obsegajoäśa oljne kapljice
GB2485327A (en) 2009-08-12 2012-05-09 Sigmoid Pharma Ltd Immunomodulatory compositions comprising a polymer matrix and an oil phase
CN102958515A (zh) 2009-12-02 2013-03-06 阿普塔利斯制药有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
EA030450B1 (ru) 2010-10-01 2018-08-31 Апталис Фарма Лимитид Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
JP6042880B2 (ja) * 2011-06-01 2016-12-14 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 放出を制御された固形剤形
US10016370B2 (en) * 2011-07-14 2018-07-10 Able Cerebral, Llc Composition, device and method for delayed and sustained release of brain energy molecules
US10953025B2 (en) * 2011-07-14 2021-03-23 Able Cerebral, Llc Composition, device and method for delayed and sustained release of brain energy molecules
US9976171B2 (en) 2011-08-08 2018-05-22 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
BR112016002574A8 (pt) 2013-08-09 2018-01-23 Allergan Pharmaceuticals Int Ltd composição de enzima digestiva, processo para a preparação da composição de enzima digestiva, e, método para o tratamento de um paciente adulto ou pediátrico com necessidade da composição de enzima digestiva
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015193730A1 (en) 2014-06-19 2015-12-23 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
MX2014008314A (es) * 2014-07-07 2016-01-06 Andres Abelino Choza Romero Procedimiento para mezclar sustancias, mediante nebulizacion.
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
CA2966801A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519365A1 (de) * 1991-06-17 1992-12-23 Byk Gulden Lomberg Chemische Fabrik GmbH Pantoprazol enthaltende orale Darreichungsformen
EP0519144A1 (en) * 1991-06-21 1992-12-23 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets
WO1993025204A1 (fr) * 1992-06-16 1993-12-23 Ethypharm Compositions stables de microgranules d'omeprazole gastro-proteges et leur procede d'obtention
EP0642797A1 (en) * 1993-09-09 1995-03-15 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
WO1997002020A1 (en) * 1995-07-05 1997-01-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
EP0773025A1 (en) * 1995-02-01 1997-05-14 Esteve Quimica, S.A. New stable galenic formulations containing an acid-labile benzimidazol compound, and production process

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519365A1 (de) * 1991-06-17 1992-12-23 Byk Gulden Lomberg Chemische Fabrik GmbH Pantoprazol enthaltende orale Darreichungsformen
EP0519144A1 (en) * 1991-06-21 1992-12-23 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets
WO1993025204A1 (fr) * 1992-06-16 1993-12-23 Ethypharm Compositions stables de microgranules d'omeprazole gastro-proteges et leur procede d'obtention
EP0642797A1 (en) * 1993-09-09 1995-03-15 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
EP0773025A1 (en) * 1995-02-01 1997-05-14 Esteve Quimica, S.A. New stable galenic formulations containing an acid-labile benzimidazol compound, and production process
WO1997002020A1 (en) * 1995-07-05 1997-01-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole

Also Published As

Publication number Publication date
PL338613A1 (en) 2000-11-06
GT199800113A (es) 2000-01-18
ZA986893B (en) 1999-01-27
ES2137862A1 (es) 1999-12-16
BG64967B1 (bg) 2006-11-30
WO1999006032A2 (es) 1999-02-11
ES2256943T3 (es) 2006-07-16
UA66800C2 (uk) 2004-06-15
EP1010423B1 (en) 2006-02-15
TR200000264T2 (tr) 2000-09-21
ES2256943T4 (es) 2007-09-16
ATE317688T1 (de) 2006-03-15
DE69833490T2 (de) 2006-10-19
CR5826A (es) 1998-09-28
US20020098242A1 (en) 2002-07-25
MY121353A (en) 2006-01-28
CA2307037A1 (en) 1999-02-11
PA8456401A1 (es) 2000-09-29
SK1032000A3 (en) 2000-11-07
HRP20000053A2 (en) 2000-08-31
JP3961217B2 (ja) 2007-08-22
AU8217398A (en) 1999-02-22
BG104193A (en) 2000-09-29
SK284892B6 (sk) 2006-02-02
HU230635B1 (hu) 2017-05-29
IL134158A0 (en) 2001-04-30
PE105199A1 (es) 1999-11-19
KR100591488B1 (ko) 2006-06-22
PL192961B1 (pl) 2006-12-29
DK1010423T3 (da) 2006-05-22
ES2156699A1 (es) 2001-07-01
CA2307037C (en) 2006-09-12
CZ298700B6 (cs) 2007-12-27
ES2137862B1 (es) 2000-09-16
TW533201B (en) 2003-05-21
CZ2000344A3 (cs) 2000-06-14
IL134158A (en) 2004-08-31
HUP0002524A2 (hu) 2001-08-28
JP2001511443A (ja) 2001-08-14
NZ502590A (en) 2001-08-31
DE69833490D1 (de) 2006-04-20
KR20010022439A (ko) 2001-03-15
NO20000435D0 (no) 2000-01-27
ES2156699B1 (es) 2002-03-01
HRP20000053B1 (en) 2003-10-31
PT1010423E (pt) 2006-06-30
NO20000435L (no) 2000-03-23
RU2207114C2 (ru) 2003-06-27
AR013242A1 (es) 2000-12-13
HUP0002524A3 (en) 2002-12-28
HN1998000113A (es) 2000-01-06
AU751609B2 (en) 2002-08-22
EP1010423A2 (en) 2000-06-21

Similar Documents

Publication Publication Date Title
WO1999006032A3 (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion
WO2001047928A3 (de) Imidazo 1,3,5 triazinone und ihre verwendung
PL339290A1 (en) Pharmacological preparation containing clodronate as its active ingredient and silicated monocrystalline cellulose as excipient
NO162965C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive alfa-(2-okso-2,4,5,6,7,7a-heksahydrotieno-(3,2-c)-5-pyridyl)-fenyl-eddiksyre-derivater.
NO175531C (no) Analogifremgangsmåte til fremstilling av terapeutisk aktive imidazo(4,5-b)-kinolinyloksyalkansyreamider
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
NO882732L (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
CA2192731A1 (en) Monohydrates of aminobenzenesulfonic acid derivatives and method for preparing thereof
NO156690C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive indanderivater.
YU94103A (sh) Novi derivati sulfonske kiseline
NO176961C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-fenyl-5, 6-dihydrobenz[cÅakridin-7-karboksylsyrer og beslektede forbindelser
FI900145L (fi) Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi
EP0285871A3 (en) Sustained release granulate without binding agent
CA2385301A1 (en) Peeling composition
NO20021727D0 (no) Fremgangsmåte for fremstilling av 3,4-metylen-dioksy- mandelisk syre
FI893121L (fi) Menetelmä farmakologisesti aktiivisten 6,21-dimetyyli-19-norprogesteronijohdannaisten valmistamiseksi
FI93216C (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1,3-dioksaanialkeenihappojohdannaisten valmistamiseksi
FI905930A7 (fi) Menetelmä uusien, farmakologisesti käyttökelpoisten bispilokarpiinihapon esterijohdannaisten valmistamiseksi
WO1997022368A3 (de) Kovalente lipid-phosphonocarbonsäure-konjugate und ihre anwendung wie antivirale arzneimittel
AU6878900A (en) 1,4-dihydropyridine-5-carboxylic acid ester derivatives and method for the preparation thereof
NO852741L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 5,6-dihydro-4h-cyklopenta (b)tiofen-6-karboksylsyre-derivater
AU1552701A (en) Process for the production of 5-oxy-7-oxabicyclo-(4.1.0)hept-3-E NE-3-carboxylic acid esters
IE811209L (en) Indole acetic acid derivatives
EP1258478A4 (en) PROCESS FOR THE PREPARATION OF CHINOLONCARBOXYLIC ACIDS AND THEIR INTERMEDIATE PRODUCTS
ECSP982605A (es) Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134158

Country of ref document: IL

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1032000

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2307037

Country of ref document: CA

Ref document number: 2307037

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 502590

Country of ref document: NZ

Ref document number: PV2000-344

Country of ref document: CZ

Ref document number: 2000/00264

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020007001023

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P20000053A

Country of ref document: HR

Ref document number: PA/a/2000/001087

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1998932185

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 82173/98

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-344

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1998932185

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007001023

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 82173/98

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020007001023

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998932185

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV2000-344

Country of ref document: CZ

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载